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Abstract
The pantetheinase vanin-1 generates cysteamine, which inhibits reduced glutathione (GSH) synthesis. Vanin-1 promotes
inflammation and tissue injury partly by inducing oxidative stress, and partly by peroxisome proliferator-activated receptor
gamma (PPARc) expression. Vascular smooth muscle cells (SMCs) contribute to neointimal hyperplasia in response to injury,
by multiple mechanisms including modulation of oxidative stress and PPARc. Therefore, we tested the hypothesis that
vanin-1 drives SMC activation and neointimal hyperplasia. We studied reactive oxygen species (ROS) generation and
functional responses to platelet-derived growth factor (PDGF) and the pro-oxidant diamide in cultured mouse aortic SMCs,
and also assessed neointima formation after carotid artery ligation in vanin-1 deficiency. Vnn1
2/2 SMCs demonstrated
decreased oxidative stress, proliferation, migration, and matrix metalloproteinase 9 (MMP-9) activity in response to PDGF
and/or diamide, with the effects on proliferation linked, in these studies, to both increased GSH levels and PPARc
expression. Vnn1
2/2 mice displayed markedly decreased neointima formation in response to carotid artery ligation,
including decreased intima:media ratio and cross-sectional area of the neointima. We conclude that vanin-1, via dual
modulation of GSH and PPARc, critically regulates the activation of cultured SMCs and development of neointimal
hyperplasia in response to carotid artery ligation. Vanin-1 is a novel potential therapeutic target for neointimal hyperplasia
following revascularization.
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Introduction
SMC proliferation, MMP activation, and migration play pivotal
roles in the progression of intimal lesions in atherosclerosis, and in
arterial injury following interventional revascularization [1]. There
are multiple mediators of intimal proliferation and neointima
formation in model arterial injury, with some evidence suggesting
that reactive oxygen species (ROS) generation and oxidative stress
are a common thread [2]. In this light, reduced glutathione (GSH)
is the major cellular thiol, and increasing cellular GSH levels can
be protective against oxidative stress [3]. GSH homeostasis is
regulated by oxidation of GSH to glutathione disulfide (GSSG),
with GSH subsequently regenerated by glutathione reductase,
expressed under the control of antioxidant response elements
[4,5]. In addition, cell and tissue levels of GSH stores are regulated
by gammaglutamylcysteine synthetase (cGCS), the rate-limiting
enzyme for GSH synthesis [6].
Vanin-1 is a widely expressed glycosyl-phosphatidylinositol
(GPI)-linked plasma membrane pantetheinase ectoenzyme, and
nitrilase superfamily member, that contains the invariant catalytic
triad residues glutamate, lysine, and cysteine [7,8]. Vanin
pantetheinase activity generates the amino-thiol cysteamine, and
regulates a variety of responses to stress [9,10]. Cysteamine
inhibits cGCS [5]. Concordantly, GSH stores in multiple tissues
are significantly increased in vanin-1 knockout mice [10].
Cysteamine also appears to decrease protective activities of
superoxide dismutase (SOD) and glutathione peroxidase (GSH-
Px) against ROS toxicity, allowing free radical production to
overwhelm antioxidant defense systems [11]. Conversely, vanin-1
deficiency is associated with both decreased superoxide produc-
tion, and resistance to oxidative stress and tissue injury induced in
vivo by paraquet or c-irradiation [5,10,12].
Several inflammatory stimuli, exemplified by PDGF, promote
SMC proliferation and migration [13,14]. Vanin-1, like several
other mediators of oxidative stress, promotes inflammation
[15,16]. For example, in intestinal epithelial cells, vanin-1
facilitates expression of certain pro-inflammatory cytokines [9].
Conversely, vanin-1 deficiency is protective in vivo for intestinal
inflammation and injury in response to both nonsteroidal anti-
inflammatory drugs and Schistosomal infection in vivo [17,18].
Vanin-1 promotes inflammation partly by suppression of both
PPARc expression and PPARc signal transduction [15]. PPARc
functions as an anti-inflammatory checkpoint in multiple inflam-
matory settings, and in a variety of cell types [18]. PPARc-
activating thiazolidinedione (TZD) treatment suppresses SMC
proliferation and migration in vitro, as well as in vivo in the intimal
hyperplasia process after arterial injury [18].
Furthermore, PPARc is expressed by normal vascular SMCs,
and arterial PPARc expression normally increases in early human
atherosclerotic lesions and 1–2 weeks after arterial balloon injury
in rodents [19,20]. PPARc activation inhibits SMC invasion, and
suppresses induction by PDGF of the transcription factor Ets-1, a
mediator of MMP expression and SMC invasion both in cultured
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3SMCs, and in vivo after balloon injury in rat aorta [21–23]. PPARc
agonists inhibit mRNA and protein expression, as well as
induction of gelatinolytic activity of MMP-9 [24], an MMP
implicated in SMC migration [25]. Here, we demonstrate that
vanin-1 plays a major role in mediating both oxidative stress and
PPARc homeostasis in SMCs, as well as migration, proliferation,
and MMP-9 activity. Furthermore, vanin-1 drives neointima
formation after carotid artery ligation in mice.
Results
Expression of Vnn1 and Vnn3 and Pantetheinase Activity
in SMCs
Vanin-1 was constitutively expressed in WT mouse aorta but
not in Vnn1
2/2 mice aortae (Fig. 1A), a finding buttressed by
aortic tissue Western blot analyses (Fig. 1B). The vanin enzyme
subfamily includes two enzymes in mice (vanin-1, and secretory
vanin- 3) [5,8]. Quantitative PCR indicated that Vnn1 deficiency
was not associated with compensatory increase in the expression
levels of Vnn3 normalized to GAPDH (ie, vanin-3 expression
relative to GAPDH not significantly different in WT vs. vanin-1
knockout SMCs (11.0360.28 WT vs.10.4360.121 Vnn1
2/2
SMCs) (Fig. 1C). Last, pantetheinase activity, demonstrated by
fluorescence using the substrate pantothenate–AMC, was robust in
WT mouse arterial sections and SMC lysates. However, the
attenuation of detectable enzyme activity in artery sections or
SMC lysates from Vnn1
2/2 mice indicated vanin-1 expression to
be required for most arterial pantetheinase activity in situ (Fig. 1
D–E).
A Vanin-1 Regulatory Circuit with GSH Mediates
Oxidative Stress in SMCs
PDGF (10 ng/ml) and diamide (5 mM), a membrane-permeable
thiol that oxidizes GSH, induced superoxide in WT SMCs; both
these responses were blunted in Vnn1
2/2 SMCs, as assessed using
the redox-sensitive dye Dihydroethidium (DHE) and by flow
cytometry) (Fig. 2A–B). Next, we observed that PDGF treatment
increased pantetheinase activity in WT but not in Vnn1
2/2 SMCs
(Fig. 2C). Treatment with the vanin-1 enzymatic product
cysteamine, a cGCS inhibitor, increased ROS levels in both
WT and Vnn1
2/2 SMCs as did treatment with another GSH-
depleting cGCS inhibitor buthionine sulfoximine (BSO; 1 mM)
(Fig. 2 D,E). GSH levels in Vnn1
2/2 SMCs were significantly
higher than in WT SMCs, with or without PDGF treatment
(Fig. 2F). However, the GSH-oxidizing agent diamide reduced
reduced GSH stores down to a comparable level in WT and
Vnn1
2/2 SMCs (Fig. 2F). Therefore, we assessed for mechanisms
beyond GSH depletion by which vanin-1 could modulate SMC
function, and focused next on PPARc.
Vanin-1 Modulated PPARc Expression Partly Regulates
SMC Proliferation and Oxidative Stress
PPARc expression was constitutively elevated in both mouse
aortic sections and cultured SMCs of Vnn1
2/2 mice compared to
WT counterparts, as confirmed by Western blotting (Fig. 3A–B).
Therefore, we assessed the inter-relationships between PPARc,
GSH, and vanin-1 in cultured SMCs, testing the potential
contribution of vanin-1 modulation of PPARc to changes in
SMC proliferation and oxidative stress mediated by vanin-1. First,
Vnn1
2/2 SMCs were relatively resistant to the capacity of diamide
to reduce PPARc expression (Fig. 3A–B). Moreover, under these
conditions, PDGF treatment decreased PPARc expression in WT
SMCs but not in Vnn1
2/2 SMCs (Fig. 3B). In contrast, diamide
significantly reduced PPARc levels in WT SMCs compared to
Vnn1
2/2 SMCs.
Second, when we effectively knocked down PPARc via siRNA
(Fig. 3C,D), we observed decreased GSH levels in both WT and
Vnn1
2/2 SMCs (Fig. 3E). Though this effect of PPARc
knockdown was not as extensive as the GSH depletion in response
to treatment with cysteamine or BSO (Fig. 3E), it linked PPARc
expression with GSH homeostasis. Third, both PDGF and
diamide increased SMC proliferation in WT SMCs, but Vnn1
2/
2 SMCs were resistant to induction of proliferation by PDGF and
diamide (Fig. 3F). Even when PPARc was knocked down, PDGF
induced proliferation more in WT than Vnn1
2/2 SMCs (Fig. 3G).
Similarly, Vnn1
2/2 SMCs also were more resistant to the capacity
of the PPARc inhibitor GW9662 to promote SMC proliferation
(data not shown). Fourth, we expressed human vanin-1 by
transfection in Vnn1
2/2 SMCs and linked increased pantetheinase
activity and vanin-1 (Fig. 4A–B) with a permissive state for SMC
proliferation to be induced by PDGF (Fig. 4C). Taken together,
vanin-1 induced oxidative stress and enhanced SMC proliferation,
doing so only partially by affecting PPARc expression in SMCs.
Conversely, PPARc expression modulated sensitivity of SMC
proliferation in response to oxidative stress.
Vanin-1 Also Modulates SMC MMP Activity and Migration
Diamide and PDGF, as well as cysteamine, induced MMP-9
activity more in WT than Vnn1
2/2 SMCs (Fig. 5A–B). In
addition, vanin-1 deficiency significantly decreased both diamide-
induced and PDGF-induced migration of cultured SMCs (Fig. 5C).
Given the collective findings on SMC proliferation, oxidative
stress, MMP activity, and migration in vanin-1 deficient SMCs, we
concluded the studies by examining the role of vanin-1 in arterial
remodeling and PPARc expression in response to carotid artery
ligation in situ.
Vanin-1 Deficiency Inhibits Post-injury Carotid Artery
Neointimal Hyperplasia
We observed robust development of neointima in WT mice
following left carotid artery ligation, but this vascular remodeling
injury response was attenuated in Vnn1
2/2 mice (Fig. 6A).
Specifically, injured carotid arteries of Vnn1
2/2 mice displayed
markedly decreased intima:media ratio (Fig. 6B) and cross
sectional area of the neointima (Fig. 6C). There was more robust
PPARc expression in injured Vnn1
2/2 arteries compared to WT
arteries (Fig. 7A–B). Last, we observed decreased cell proliferation,
assayed by Ki-67 staining, in both the media and neointima in the
injured Vnn1
2/2 mouse arteries (Fig. 7C–D).
Discussion
Oxidative stress, including NADPH oxidase activity [2,26–30],
and regulation of PPARc [25], are among the numerous factors
implicated in activation of SMCs in vascular remodeling [21].
Given putatively redundant pathways for vascular remodeling, the
net individual roles of GSH stores and PPARc in the process, let
alone potential impact of their combined role, had not previously
been clear. This study identified vanin-1 as a central mediator of
oxidative stress and an inhibitor of constitutive PPARc expression
in SMCs. Vanin-1 promoted GSH depletion and MMP activation,
and vanin-1 critically mediated PDGF-induced proliferation and
migration in cultured SMCs. The vanin-1 enzymatic product
cysteamine also promoted oxidative stress, MMP activity, and
decreased PPARc expression in SMCs. These findings were
buttressed by the demonstration that vanin-1 knockout markedly
limited in vivo post-injury neointima formation. Moreover, vanin-1
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PPARc expression relative to ligated WT control carotid arteries.
In our in vitro studies, SMCs from Vnn1
2/2 mice failed to
demonstrate increased migration in response to PDGF and
diamide. We also observed that regardless of whether diamide
or PDGF was promoting oxidative stress, vanin-1 played a crucial
role in regulating generation of ROS. Diamide acts by formation
of a protein-protein internal disulfide bond, without formation of a
sulfenic acid intermediate [31]. PDGF-BB-induced AP-1 activity
and cell proliferation are secondary to alkylation of cysteinyl
residues, essential for the catalytic activities of various enzymes,
transcription factors and/or transporters [32], and PDGF effects
in SMCs were blocked by addition of catalase or antioxidants in
prior studies [4]. It is noteworthy that SMCs express multiple
enzymes that generate ROS, including phospholipases,
cytochrome P450, cyclooxygenase, lipoxygenase, xanthine
oxidase, and ribonucleotide reductase, as well as a functional
NADPH oxidase complex [26–30]. Moreover, vascular NADPH
oxidase and ROS mediate functionally significant signal trans-
duction in SMCs [26–30]. Vanin-1 is likely active in regulating
SMC function because cellular GSH homeostasis modulates not
only oxidative stress but also pro-inflammatory sequelae [26]. In
this context, GSH depletion is one mode for enhancement of
inflammation signaling pathways such as p21ras, MAP kinase
activity, and NF-kB nuclear translocation [26,33]. Our demon-
stration of a major role of vanin-1 in depleting SMC GSH stores
identifies a novel pro-inflammatory activation switch in SMCs. In
this study, siRNA-induced silencing of PPARc, by itself, depleted
SMC GSH levels and modulated the threshold for SMC activation
in response to oxidative stress. Our results, for SMCs, treated with
PPARc siRNA and pharmacologic PPARc inhibition, indicated
that vanin-1 enhanced SMC activation responses in part by
modulation of PPARc expression. PPARc exerts substantial effects
on SMC proliferation in vitro and in vivo [19,20,34–36]. In addition,
PPARc activation is an SMC anti-inflammatory control point that
inhibits activation of NF-kB, and suppresses SMC proliferation
induced by PDGF and angiotensin II [19,20,34–36]. PPARc
activation also inhibits SMC invasiveness, and migration mediated
by MMP activation [20]. Multiple overlapping mechanisms
regulate PPARc expression in SMCs [19,20,35]. Importantly,
lack of vanin-1 robustly inhibited PPARc expression in SMCs,
and, conversely, PPARc expression in situ was increased
constitutively, and after carotid arterial injury, in Vnn1
2/2 mouse
arteries.
Limitations of the current study include confinement of the
scope of in vivo analyses to carotid artery ligation, and the inherent
Figure 1. Constitutive vanin-1 expression in aorta and pantetheinase activity in cultured mouse aortic SMCs. A, Histologic sections of
aortae from WT and Vnn1
2/2 mice were immunohistochemically stained for vanin-1 (brown positive staining). B, Vanin-1 analyzed by aortic tissue
Western blotting. C, In isolated aortic SMCs, vanin-1 and vanin-3 isoenzyme mRNA expression levels were compared by real-time PCR, normalized to
GAPDH mRNA in samples from WT and Vnn1
2/2 mice. *P,0.05, WT vs. Vnn1
2/2 control. D, Aortic sections were incubated with the substrate
pantothenate–AMC and constitutive vanin-1 immunofluorescence (green) is shown in carotid sections of WT and Vnn1
2/2 mice. E, Pantetheinase
activity is shown from cultured SMC lysates of mice of indicated genotypes; results from SMCs of different animals are shown as distinct plots, with
each result the mean 6 SD of 3 independent experiments. *P,0.05 for WT vs. Vnn1
2/2.
doi:10.1371/journal.pone.0039106.g001
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what effects vanin-1 has in endothelial cells, macrophages, and in
other resident and infiltrating cell types in the artery wall that
modulate vascular remodeling. Vanin-1 pantetheinase effects on
individual elements in ROS generation, such as NADPH oxidase
activity and mitochondrial activities, merit further investigation.
We also restricted our analyses on PPAR to PPARc. Net effects of
vanin-1 on individual PPARc isoforms, let alone potential effects
on other PPARs that affect the artery [35], remain to be
investigated. Oxidative stress is difficult to target in arteries and
other tissues, since multiple mechanisms contribute to reactive
oxygen species generation and elimination [26–30]. Moreover,
PPARc activity has been difficult to target for vascular and other
disease in clinical medicine, since PPARc activating thiazolidine-
diones (TZD) drugs can cause side effects, including severe and
potentially lethal fluid retention mediated by renal effects of
PPARc activation [37]. In this context, it is noteworthy that vanin-
1 knockout mice are viable and grossly normal. Our study reveals
vanin-1 to be a novel inflammatory switch for vascular remodeling
diseases, via dual effects on PPARc and oxidative stress.
Methods
Materials
Diamide (1,1’-azobis(N,N-dimethylformamide)), PDGF-BB, and
all chemical reagents were obtained from Sigma-Aldrich (St.
Louis, MO), unless otherwise indicated. Antibodies against b-actin
and Vanin-1 were from Cell Signaling (Boston, MA) and Santa
Cruz Biotechnology, Inc (Santa Cruz, CA) respectively. b-alanine
7-amido-4-methylcoumarin trifluoroacetic acid was from Chem-
Impex International Inc (Wood Dale, IL). The GSH assay kit was
from Cayman Chemicals (Ann Arbor, MI) and the cell prolifer-
ation assay kit was from Promega (Madison, WI). DHE was from
Molecular Probes (Grand Island, NY). Anti-Ki-67 antibody was
from Abcam (Kendall Square, Cambridge, MA).
Mice Studied
All animal procedures were performed humanely and followed
institutionally approved protocols, with procedures in compliance
with the standards for care and use of laboratory animals of the
Institute of Laboratory Animal Resource. Vnn1
+/2 mice were
backcrossed for more than nine generations on a C57BL/6
background, and then interbred to generate and study Vnn1
2/2
mice and wild-type littermate progeny on the same background, as
described [10,38]. All animal experimentation was assessed and
approved by the IACUC (Institutional Animal Care and Use
Committee) of the San Diego Veterans Affairs Medical Center.
Carotid Artery Ligation
Animals were anesthetized by intraperitoneal (i.p.) injection of
15 mg/kg Ketamine (phoenix pharmaceutical inc, ST. Joseph,
MO), 1.6 mg/kg Xylazine (Akorn Inc, Decatur, IL), and 1.2 mg/
kg Acepromazine (Boehringer Ingelheim, Ridgefield, CT). In
brief, the left common carotid artery, dissected from surrounding
connective tissue, was ligated through a midline neck incision just
proximal to its bifurcation, using 6–0 silk ligature. In control
groups, dissection of the left common carotid artery from the
surrounding connective tissue was performed without ligation.
Twenty-one days after injury or simple dissection, animals were
anaesthetized and perfused with PBS, followed by 4% parafor-
maldehyde. Carotid arteries were excised, and then embedded in
paraffin. Cross-sections (6 microns) were taken starting at the
ligation site and stained with hematoxylin and eosin.
SMC Culture and Transfection
Mouse aortic SMCs were isolated by enzymatic digestion [39]
from Vnn1
2/2 and control littermate WT mice. Cells were
cultured in DMEM supplemented with 10% FBS, 100 Units/ml
penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine at
37uC in a humidified 95% air and 5% CO2 incubator. The
purity of each mouse SMC preparation in culture was confirmed
by immunocytochemistry for a-smooth muscle actin. Cells were
passaged at 1:3 ratio. Experiments were performed using cells
between passage 3–8, and serum-deprived conditions were
generated by incubation for 24 h in DMEM containing 0.1%
FBS. The small interfering RNA (siRNA) and scrambled RNA
(scRNA) employed were purchased from Santa Cruz Biotech-
nology (Santa Cruz Biotechnology, Inc. Santa Cruz, CA).
Transfection was done by manufacturer recommended protocol.
Vnn1
2/2 SMCs were transfected with pCMV-VNN1 full-length
plasmid DNA using 293T transient overexpression reagent
(Abnova, Walnut, CA, Catalog # H00008876-T01), as per
manufacturer instructions.
Quantitative Real-time RT-PCR
Total RNA was isolated using Trizol (Invitrogen, San Diego,
CA), and cDNA was transcribed from 1 mg of RNA using
Superscript III enzyme (Invitrogen), and random primers. Reverse
transcription and quantitative real-time RT-PCR were performed
using the LightCycler 2.0 (Roche Diagnostics, San Francisco, CA),
as described [38]. Oligonucleotides were designed for mouse
vanin-1, using Roche Primer Express software: vanin-1, forward
5’-TGGTAGTTCAGTGGACACG-3’, and reverse 5’- AGG-
GAAGACATACCGGG-3’, and mouse vanin-3, 5-
CCGTTTGGGAAGTTTGGC-3’ and reverse 5’-CGAATG-
GAATGGAACTGCTGA-3’. Following amplification, a mono-
color relative quantification of the target gene and reference
(glyceraldehyde-3- phosphate dehydrogenase; (GAPDH, F 59-
CATCCCAGAGCTGAACG-39,R5 9- CTGGTCCTCAGTG-
TAGCC-39) was normalized for target gene to GAPDH mRNA
(glyceraldehyde-3-phosphate) copy ratios using the manufacturer’s
LightCycler software (version 4.0).
Figure 2. Vanin-1 and cysteamine modulate SMC superoxide production and GSH content in response to diamide and PDGF. A,
SMCs isolated from Vnn1
2/2 and WT mouse aortae were growth-arrested in 0.1% calf serum for 24 h, and exposed to dihydroethidium (DHE) (10 mM).
Images were captured 30 min after stimulation with diamide (5 mM) and PDGF (10 ng/ml). B, Superoxide production was quantified by flow
cytometry (excitation and emission wavelengths 488 nm and 610 nm, respectively). C, WT and Vnn1
2/2 SMCs were treated with PDGF (10 ng/ml) for
24 h, and pantetheinase activity measured (*WT+PDGF vs. Vnn1
2/2 +PDGFand WT control). D, In SMCs treated with cysteamine (500 ng/ml) or BSO
(1 mM) for 48 h, DHE fluorescence was measured. E, WT and Vnn1
2/2 SMCs were treated with PDGF (10 ng/ml) for 24 h, and GSH content measured
via enzymatic recycling assay. Data are mean 6 SD of 3 independent experiments. *P,0.05 vs. control; **control vs. PDGF in WT, # control vs.
diamide in WT and Vnn1
2/2. F, SMC superoxide production in response to cysteamine and BSO treatment was quantified by flow cytometry
(excitation and emission wavelengths 488 nm and 610 nm, respectively). Data are mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0039106.g002
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Aortic tissue and SMCs were lysed in RIPA buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mM sodium fluoride,1 mMsodium
orthovandate, 1 mM phenylmethylsulfonyl fluoride, 1 mM
EDTA, 10 mg/ml leupeptin, 1 mg/ml aprotinin) and protein
extracts separated by 10% SDS-PAGE, and transferred to
Immobilon-P membranes. After blocking, blots were incubated
with primary antibodies overnight at 4uC, and detection of antigen
using secondary antibody conjugated with horseradish peroxidase,
and enhanced chemiluminescence, as well as scanning densitom-
etry, were done as described [38].
Pantetheinase Activity Assay
The substrate, pantothenate–AMC was chemically synthesized
using b-alanine 7- amido-4-methylcoumarin trifluoroacetic acid
(TFA) salt (H- b -Ala-AMC.TFA, 36 mg, 1eq) and R-(-)-
pantolactone [40]. To assay pantetheinase activity, we used
pantothenate–AMC as substrate at 37uC for 30 min, with the
hydrolysis catalyzed by vanin-1 yielding pantothenic acid and
detectable free fluorescent AMC (excitation 340 nm, emission
Figure 3. Relationships between PPARc expression, GSH content, and vanin-1 in arteries and cultured SMCs. A–B, We treated cultured
aortic SMCs with diamide (5 mM) and/or PDGF (10 ng/ml) for 48 h and PPARc expression was analyzed by Western blot, and densitometry. P,0.05 for
# Vnn1
2/2 control vs. WT control SMCs; *Vnn1
2/2 control vs. diamide treated SMCs; **WT SMCs vs. PDGF and diamide treated SMCs, respectively. C–
D, SMCs were transfected with PPARc siRNA, and then PPARc expression analyzed by Western blot. *P,0.05 for Vnn1
2/2 vs. WT SMCs, # Vnn1
2/2
control vs. PPARc siRNA, **PPARc siRNA WT SMCs. E, WT and Vnn1
2/2 SMCs were treated with cysteamine (500 ng/ml) or BSO (1 mM), and GSH
content determined after deproteinization. Data pooled from 3 experiments done in triplicate.
# P,0.05 Vnn1
2/2 vs. WT SMCs, *control vs. PPARc
siRNA,**control vs. cysteamine in both Vnn1
2/2 and WT SMCs,
L control vs. BSO treatment in both Vnn1
2/2 and WT SMCs. In Panel F, WT and Vnn1
2/
2 SMCs were treated with diamide (5 mM) or PDGF 10 ng/ml) for 24 h, and cell proliferation compared. *P,0.05 vs. control. G, SMC proliferation
using PPARc siRNA knockdown. Data are mean 6 SD of 3 independent experiments. *P,0.05 control vs. PPARc siRNA, **PPARc siRNA vs. PPARc
siRNA + PDGF in WT and Vnn1
2/2 SMCs.
doi:10.1371/journal.pone.0039106.g003
Figure 4. Vanin-1 mediates SMC proliferation in response to PDGF. Vanin-1 was expressed in Vnn1
2/2 SMCs by transfection using pCMV-
VNN1 expression vector. A, Pantetheinase activity was measured in Vnn1
2/2 SMCs after transfection and B, Western blot analysis confirmed vanin-1
expression after transfection. C, Following pCMV-VNN1 or empty vector transfection, SMCs were treated with PDGF (10 ng/ml) for 24 h, and
proliferation measured. Data are mean 6 SD of 3 independent experiments. *P,0.05 Vnn1
2/2 SMCs control vs. Vnn1
2/2 + pCMV-VNN1+ PDGF.
doi:10.1371/journal.pone.0039106.g004
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2/2 SMCs. A, Serum-starved SMCs were treated with PDGF (10 ng/ml),
cysteamine (500 ng/ml) or diamide (5 mM) for 48 h, and conditioned media analyzed for MMP-9 activity by gelatin zymography. B, Densitometric
analysis of enhanced MMP-9 activity in WT compared to Vnn1
2/2 SMCs. Data pooled from 3 independent experiments for densitometry. C, We
assayed migration in SMCs treated with diamide (5 mM) or PDGF (10 ng/ml), as described in the Methods. Total number of SMCs migrated/well after
48 h treatment with diamide or PDGF are shown. Data are mean 6 SD of 3 independent experiments. *P,0.05 vs. control.
doi:10.1371/journal.pone.0039106.g005
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with potassium phosphate buffer (100 mM, pH 7.5) containing
0.1% Triton X-100 and 0.6% sulfosalicylic acid. Protein
concentrations were determined by bicinchoninic acid (BCA)
protein assay. Enzymatic assay was carried out using 5 mg of cell
lysate in phosphate buffer (100 mM potassium phosphate buffer,
pH 7.5) containing 2 mM pantothenate- AMC, 0.01% BSA,
0.5 mM DTT, 5% DMSO, and 0.0025% Brij-35 in a total
volume of 100 ml reaction mixture. Reactions were carried at
37uC in the presence or absence of cell lysate and the fluorescence
(Excitation 350 nm and emission 460 nm) was recorded every
2 min, with the change in fluorescence measured over a 30 min
period. A standard curve was generated using purified recombi-
nant vanin-1 (Abnova, Walnut, CA, catalog # H00008876-P01)
under the same buffer conditions described above. Vanin-1
activity was normalized for total protein content. Pantetheinase
activity was calculated by taking the slope at 30 min, fitting the
data to the standard curve and normalizing for total protein
content.
Quantification of GSH
To determine GSH and oxidized glutathione levels, we used an
enzymatic recycling assay (glutathione assay kit, Cayman Chem-
icals, Ann Arbor, MI) in the presence of glutathione reductase. We
spectrophotometrically determined 5-thio-2-nitrobenzoic acid
generation in deproteinated cells [38].
Measurement of Superoxide Generation
Superoxide generation in SMCs was measured, as described
[41], in cells incubated with dihydroethidium (DHE) (10 mM) in
PBS at 37uC in the dark for 30 min in a 5% CO2 humidified
chamber. Propidium iodide (10 mg/ml) was added 1 min before
flow cytometry and examined by FACS with excitation at 488 and
emission at 610 nm. Flow cytometry (FACScan; BD Biosciences,
San Jose, CA) was used to select a homogeneous population of
10,000 live cells. Bivariate flow cytometry was performed with a
FACS scan, and the data were analyzed with Cell Quest software
(Becton Dickinson, San Jose, CA, USA), in the cell population
from which apoptotic cells were gated out against forward and side
scatter or PI-positivity. The geometrical mean of ethidium
fluorescence intensity (excitation 488 and emission at 610 nm) in
thepopulation was used for analysis. Alternatively, samples were
examined by fluorescence microscopy (Advanced Microscopy
Group, EVOS FL).
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections were
deparaffinized and followed by rehydration, endogenous peroxi-
dase activity was quenched using 3% H2O2. Followed by
blocking, the sections were incubated overnight at 4uC with
primary antibody against vanin-1, PPARc (1:100) and Ki-67
(1:100) as a cell proliferation marker, sections were then incubated
with biotinylated secondary antibody and peroxidase-labeled
Figure 6. Reduced neointima formation after carotid ligation in Vnn1
2/2 mice. A, Cross sections of representative H&E stained carotid
arteries of Vnn1
2/2 and WT mice are shown, 21 days after carotid ligation. B–C, For each arterial section, intimal and medial areas were measured, and
intima:media ratio calculated. Morphometric analysis was performed using NIH Image Analysis Software. Data are mean 6 SD of 3 independent
experiments *P,0.05 WT vs. Vnn1
2/2.
doi:10.1371/journal.pone.0039106.g006
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by exposing sections to the substrate, 3,39–diaminobenzidine
tetrahydrochloride (DAB) and counterstaining with 1% methyl
green. For negative control sections, PBS was substituted for the
primary antibody. We calculated percentage of positive staining
SMCs in media and neointima (relative to total cell number) in 5
different 20 X magnification fields in each section, studying 8
sections from each control and ligated sample from each mouse.
SDS-PAGE/Western Blot Analysis
SMCs were lysed in RIPA buffer (50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, 10 mM sodium fluoride, 1 mM sodium orthovanadate,
1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 10 mg/ml
leupeptin, 1 mg/ml aprotinin). Protein extracts (35 mg) were
separated by 10% SDS-PAGE, and transferred to Immobilon-P
membranes, and, after blocking, blots were incubated with
primary antibodies for 18 h at 4uC. The membrane was washed,
and then incubated withrespective secondary antibody conjugated
with horseradish peroxidase. Enhanced chemiluminescence re-
agent (Thermo Scientific, Rockford, IL,) served as substrate
solution, used according to manufacturer instructions. Horizontal
scanning densitometry of films was performed using universal
hood densitometry (Bio-Rad, Hercules, CA).
Assay of MMP Activity
Gelatinase activity was determined by zymography as previ-
ously described [42,43]. Equal amounts of conditioned media
from identical numbers of cells, grown under serum free
conditions for 48 h, were loaded onto 10% SDS-polyacrylamide
gels containing 0.1% gelatin, and zymography was performed.
After electrophoresis, gels were incubated for 45 min in renatur-
ation buffer and in developing buffer (Invitrogen, Carlsbad, CA)
for 24 h at 37uC. Gels were stained with Coomassie blue; clear
bands indicated active enzymes (MMP-9 pro-form, 92 kDa; active
form, 83 kDa). Enzymatic activity was estimated by densitometry
of negative-image zymographic gels and measured in OD units.
Cell Proliferation and Migration Studies
We used the Invitrogen non-radioactive Cell Proliferation Assay
kit, per manufacturer instructions, to determine cell proliferation.
SMC migration was assayed using the Transwell system (Corning,
NY), with a polycarbonate membrane in six-well plates. SMCs
were plated at a concentration of 1.0x 10
6 cells/ml. Numbers of
cells migrated per well, after 48 h treatment with PDGF or
diamide, were determined by thiozolidine bluestaining. Images
were analyzed using a microscope with digital camera (Advanced
Microscopy Group, Bothell, WA).
Statistical Analyses
Unless otherwise indicated, data are presented as the mean 6
SD of determinations from 3 or more experiments. Results were
compared by one-way ANOVA followed by Bonferroni multiple-
comparison analysis. A value of p,0.05 was used to define
statistical significance.
Author Contributions
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Figure 7. Immunohistochemical staining for PPARc and the cell
proliferation marker Ki-67 in uninjured and injured carotid
arteries. A, Paraffin-embedded, uninjured and injured aortae of the
indicated genotypes were cut into 6 mm sections for immunohisto-
chemistry, with PPARc positive media and neointimal cells staining dark
brown (arrowheads) in methyl green counterstained sections. B,
Percentage of arterial media and neointimal PPARc positive cells,
determined as described in Methods. C, Immunohistochemical detec-
tion of Ki-67 in representative WT and Vnn1
2/2 carotid sections. D,
Percentage of arterial media and neointimal Ki-67 positive cells. Data are
mean 6 SD of 3 independent experiments. *P,0.05 WT vs. Vnn1
2/2.
doi:10.1371/journal.pone.0039106.g007
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